Purpose: Triple negative breast cancer (TNBC) has had poor prognosis compared with the luminal subtype. And there has been no benefit from doxorubicin. However, the addition of paclitaxel is known to improve both disease-free survival (DFS) and overall survival (OS). The aim of our study was to assess the effect of the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide in TNBC. Methods: We randomly selected 87 women from 104 women with TNBC who had been randomly assigned to receive doxorubicin (60 mg per square meter of body-surface area) plus cyclophosphamide (600 mg per square meter) for four cycles, followed by four cycles of paclitaxel (175 mg per square meter) or two more cycles of doxorubicin plus cyclophosphamide. Due to predictions of clinical outcomes in women who receive adjuvant paclitaxel based chemotherapy, immunohistochemical analyses of these tissue specimens for CK5/6 were used. Results: Among patients with TNBC, 24 patients (27.6%) were classified as CK5/6-positive triple negative type. Twelve patients were classified as paclitaxel chemotherapy group and 75 patients were classified as no paclitaxel group. No interaction was observed between DFS or OS and paclitaxel regimens. CK5/6 was, however, not associated with a significant benefit from paclitaxel in our study. 
2) Immunohistochemistry
All data were collected from the pathology reports. The combination of ER-negative, PgR-negative, and HER2- negative expression was defined as triple-negative breast cancer.
3) Statistical analysis
The primary end point was disease-free survival, defined in the parent study as the interval from study entry until the first local or distant recurrence or death due to any cause. Statistical tests were performed using the SPSS 12. presented for the survival function, and differences in survival were analyzed using the log rank test. Cox proportional hazards regression analysis was used to estimate hazards ratio and 95% confidence intervals for overall survival and disease-free survival as defined by local recurrence and distant recurrence, whichever occurred first.
Associations between specific histopathological and clinical survival estimates and curves were established using the Kaplan-Meier method and differences in observed survival distribution among patient subgroups were tested with two-sided log-rank test. All survival rates were presented with their standard errors. We used Pearson's correlation to determine the association of pairs of explanatory Table 4 . The univariate analysis for prognostic factors associated with disease-free survival in (Fig. 1) . The apparent interaction between overall survival and the addition of paclitaxel in TNBC group was not significant (P=0.3770) (Fig. 2) . 
CONCLUSION
We observed an interaction between the CK5/6 status of the TNBC and the benefit of adjuvant paclitaxel in TNBC who received four cycles of doxorubicin plus cyclophosphamide. Our results indicate that CK5/6 positivity can not predict improvement in disease-free survival and overall survival by the addition of paclitaxel to doxorubicin plus cyclophosphamide. But because our study is small size study, more abundant patients' data will be needed to evaluate of the CK5/6's predictive role.
